Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I/II Study of Neratinib and Divalproex Sodium (Valproate) in Advanced Solid Tumors, With an Expansion Cohort in Ras-Mutated Cancers

Summary

The purpose of this phase I/II study is to determine the recommended phase II dose (RP2D) of the combination of neratinib and sodium valproate when given to patients with advanced solid tumors.

General Information

NCT#: NCT03919292
Study ID: MCC-17-13821
Trial Phase: Phase I/II

Trial Sponsor: Virginia Commonwealth University, Puma Biotechnology, Inc.
Therapies Used in This Trial: Neratinib, Sodium valproate

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search